Life Sciences Logistics Provider Expands into China
The Life Sciences logistics solutions provider, Biocair has recently expanded its operations into China. The opening ceremony, held on November 12th was attended by Carma Eliott, the British Consul General in Shanghai, who cut the ribbon together with Andy King, the Managing Director of Biocair. The British Consul general congratulated Biocair on the issue of their new Chinese Business Licence. She re-affirmed the British Government’s support of the Life Sciences sector and acknowledged the vital logistics role for research materials and clinical trial samples that Biocair can now provide companies in China.
Biocair, established since 1987, is a proven international specialist in transporting temperature sensitive biological materials and drugs for clinical trials in and out of the main pharmaceutical and biopharmaceutical clusters in UK, Europe, USA, South America, Russia, Japan, and India. The new logistics operation in Shanghai has extended their Asia service offering. Andy King commented; “This expansion into China is a key step in our international business development plan in response to growing customer demand in the region”. He went on to say: “We really appreciated all the encouragement and support we have had from customers, which helped us make this investment decision to enter the China market.”
Biocair used the consultancy company Asiasetup to assist in setting up operations in China. Asiasetup was able to gain ‘Wholly Foreign Owned Enterprise’ approval at Municipal level in two weeks and Biocair’s business license was granted two weeks later.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
